Overview
Initiative type
Model of Care
Status
Close
Published
10 January 2018
Summary
In many cases, the benefits of frequently prescribed medications in older adults do not outweigh the risks of harm. These medications are associated with adverse effects, including—but not limited to—impaired physical and cognitive function, sedation, falls and fractures, and an increased risk of mortality. Additionally, their use in older adults often leads to economic consequences, such as a higher likelihood of hospitalisation.
Key dates
Dec 2016 - Dec 2017
Implementation sites
All Queensland Public Hospitals
Aim
The project aims to investigate the use of antipsychotics, benzodiazepines and medicines with significant anticholinergic action in older adult inpatients of Queensland Health public hospitals. The project also aims to identify the frequency of use of these medicines at various sites throughout the state, including metropolitan, regional and remote hospitals. Their use within various clinical units will also be investigated.
Outcomes
- provides a baseline understanding of the frequency of use of antipsychotics, benzodiazepines and medicines with significant anticholinergic action, in older adult inpatients of Queensland Health public hospitals.
- identifies if remoteness impacts likelihood of use of these medicines.
- identifies if their use is more likely in certain clinical areas.
- identifies if falls risk assessment tools impact likelihood of use of these medicines.
- identifies the frequency with which indications are annotated for the audited medicines on the medication record form.
Background
Frequently prescribed medicines in older people include those with anticholinergic and sedative effects. These medicines are used in adults to treat medical conditions that often occur later in life, such as urinary incontinence, sleep and pain disorders, dementia and mental illness.
A clinical audit of the use of antipsychotics, benzodiazepines and medicines with significant anticholinergic action in Queensland Health public hospitals throughout the state has not been undertaken previously. The audit intends to identify the frequency of use of these medicines at various sites throughout the state, including metropolitan, regional and remote hospitals. Their use within various clinical units will also be investigated.
The results of the audit will be used to identify common areas within Queensland Health public hospitals were quality improvement initiatives will be most effective to optimise the use of these medicines in older inpatients.
Key contact
Network Coordinator
Queensland Dementia, Ageing and Frailty Clinical Network (QDAF)
Healthcare Improvement Unit